Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could tame lupus flares in major trial

NCT ID NCT05648500

Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 16, 2026 · Updated 7 times

Summary

This phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers will measure how well the drug controls disease activity and check its safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cenerimod (a tablet taken by mouth)
What this could lead to
If it works, cenerimod could become a new treatment option to better control lupus symptoms when added to current therapy.
What could go wrong
This is still a phase 3 trial, so results are not yet confirmed. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

470 people

The number who actually took part.

Started

Dec 2022

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria at screening: * Signed Informed Consent Form (ICF) prior to any study-mandated procedure. * Diagnosis of Systemic Lupus Erythematosus (SLE) made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism / American College of Rheumatology Criteria. * A modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score ≥ 6 and clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). The mSLEDAI-2K score does not include "leukopenia". * British Isles Lupus Assessment Group-2004 (BILAG) Grade B in ≥ 2 organ systems or a BILAG Grade A in ≥ 1 organ system. * Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 visual analog scale. * Currently treated with one or more of the following SLE background medications: * Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine). * Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤1.44 g/day). * Azathioprine (≤ 2 mg/kg/day). * Methotrexate (≤ 25 mg/week). * Oral Corticosteroids (OCS): * if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent. * if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent. * Belimumab (≤10 mg/kg every 4 weeks intravenously \[i.v.\], or 200 mg/week subcutaneously \[s.c.\]). Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening. • For women of childbearing potential (WoCBP): * Negative serum pregnancy test at Screening. * Agreement to undertake monthly urine pregnancy tests from Randomization up to 6 months after study treatment discontinuation. * Agreement to use a highly effective method of contraception from Screening (Visit 1) up to 6 months after study treatment discontinuation. Inclusion criteria at randomization: * A clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). * BILAG Grade B in 2 or more organ systems or a BILAG Grade A in 1 or more organ system. * PGA score ≥ 1.0 on a 0 to 3 visual analog scale. * Presence of at least one of the following biomarkers of serological evidence of active SLE (in a Screening sample as measured by central laboratory): * Anti-dsDNA antibodies elevated above normal, * Antinuclear antibodies with a titer of at least 1:160, * Anti-Smith antibody elevated above normal. * Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Randomization (except OCS, which must be stable for at least 15 days prior to Randomization): * Antimalarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine); * Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44g/day); * Azathioprine (≤ 2 mg/kg/day); * Methotrexate (≤ 25 mg/week); * OCS: * if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent. * if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent. * Belimumab (≤ 10 mg/kg every 4 weeks i.v. or ≤ 200 mg/week s.c.). * WoCBP must have a negative urine pregnancy test at Randomization. Main Exclusion Criteria: * Pregnant, planning to be become pregnant up to Final Study Visit, or lactating women. * Severe active central nervous system lupus or active severe or unstable neuropsychiatric SLE including but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex: * That would make the subject unable to fully understand the ICF; OR * Where, in the opinion of the investigator/delegate, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated. * A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, autoimmune hepatitis or uncontrolled autoimmune thyroid disease. * History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders. * Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within 6 months prior to Screening. * Resting heart rate \< 50 bpm as measured by the 12-lead ECG at Screening or at Randomization. * An elevated QT interval corrected according to Fridericia's formula (QTcF) interval of \> 470 ms (females) / \> 450 ms (males) at Screening or at Randomization. * History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history, lung function, and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening. * History of clinically relevant bronchial asthma or chronic obstructive pulmonary disease that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening. * History or presence of malignancy (except for surgically excised and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma), lymphoproliferative disease, or history of total lymphoid irradiation within 10 years prior to Screening. * Presence of any of the following abnormalities detected during the ophthalmological evaluation and/or by optical coherence tomography (OCT) during screening: * Macular edema of any cause: diabetic, cystoid, tractional. * Foveal degeneration, macular hole, macular pseudohole, hereditary or degenerative maculopathies. * Active uveitis, papilledema. * Retinal neovascularization of any cause and in any location. * History of chronic liver or biliary disease (other than Gilbert's Syndrome) or subjects with alanine aminotransferase or aspartate aminotransferase \> 3 × Upper Limit of Normal (ULN) or total bilirubin \> 1.5 × ULN (unless in the context of known Gilbert's Syndrome). * Significant hematology abnormality at screening assessment: * lymphocyte count \< 500 /μL (0.5 × 10\^9/L); * hemoglobin \< 7 g/dL; * white blood cell count \< 2000/μL (2.0 × 10\^9/L); or * platelets \< 25000/μL (25 × 10\^9/L). * Estimated glomerular filtration rate \< 15 mL/min/1.73 m\^2. * Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: * β-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other anti-arrhythmic or heart-rate -lowering systemic therapy. * QT-prolonging drugs with known risk of torsade de pointes irrespective of indication. * Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: * Cyclophosphamide, cyclosporine, voclosporin, tacrolimus, sirolimus, etc. * Pulse methylprednisolone. * Vaccination with live vaccines (including live vaccines for COVID-19). * Intra-articular, intramuscular or i.v. CS within 6 weeks prior to Randomization. * Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: * Leflunomide. * i.v. immunoglobulins. * Treatment with any investigational agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Randomization. * Treatment with B cell-depleting biological agents (e.g., rituximab or ocrelizumab) or biological immunosuppressive agents (e.g., anti-tumor necrosis factor \[TNF\], anti-interleukin \[IL\]-1, anti-IL6 therapies), within 12 months prior to Randomization. * Treatment with anifrolumab within 6 months prior to Randomization. * Treatment with any of the following medications any time prior to Screening: * Alemtuzumab, * Sphingosine-1-phosphate receptor modulators (e.g., fingolimod), * Subjects previously randomized to cenerimod or placebo in any trial involving cenerimod.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus erythematosus, systemic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease connective tissue disorder immune system disorder systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus erythematosus, systemic

Contacts and locations

Locations

  • "University Multiprofile Hospital for Active Treatment - Pulmed" OOD

    Plovdiv, 4002, Bulgaria

  • 424 General Military Hospital

    Thessaloniki, 56429, Greece

  • Accurate Clinical Research Inc.

    Baytown, Texas, 77521, United States

  • Accurate Clinical Research Inc.

    Houston, Texas, 77089, United States

  • Accurate Clinical Research Inc. - Lake Charles

    Lake Charles, Louisiana, 70605, United States

  • Acibadem City Clinic Diagnostic-Consultative Center" EOOD, 127 Okolovrasten pat, Mladost

    Sofia, 1784, Bulgaria

  • Advance Quality Medical Research

    Orland Park, Illinois, 60462, United States

  • Allied Biomedical Research Institute

    Miami, Florida, 33155, United States

  • Alloy Clinical Research, LLC

    Kissimmee, Florida, 34741, United States

  • Aprillus Asistencia e Investigacion

    Buenos Aires, C1046AGA, Argentina

  • Arsema Clinica Adventista Belgrano

    Buenos Aires, C1430EGF, Argentina

  • Assured Care Plus Hospital

    Nashik, 422101, India

  • Augusta University

    Augusta, Georgia, 30912, United States

  • Axon Clinical Research -Baltimore

    Baltimore, Maryland, 21237, United States

  • Biológicos Especializados S.A. de C.V.

    Mexico City, 06700, Mexico

  • Bluecare salud SAS

    Bogotá, 110221, Colombia

  • Bronx Care Health and Wellness Center

    The Bronx, New York, 10457, United States

  • CHU Félix Guyon Site Nord

    Saint-Denis, 97400, France

  • CHU de Purpan

    Toulouse, 31059, France

  • CITER, Centro de Investigación y Tratamiento de las Enfermedades Reumáticas S.A. de C.V.

    Mexico City, 06700, Mexico

  • CPClin - Centro de Pesquisas Clínicas

    São Paulo, 01228-200, Brazil

  • California Research Institute

    Huntington Park, California, 90255, United States

  • Catholic University of Daegu (Daegu Catholic University Medical Center)

    Daegu, 42472, South Korea

  • Centro Integral de Reumatología

    San Miguel de Tucumán, T4000DVB, Argentina

  • Centro Mineiro de Pesquisas

    Juiz de Fora, 36010-570, Brazil

  • Centro Multidiciplinar de Estudos Clínicos- CEMEC

    São Bernardo do Campo, 09715-090, Brazil

  • Centro Multidisciplinar de Pesquisa Clínica (Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre, 90050-170, Brazil

  • Centro de Atención e Investigación Cardiovascular del Potosí, S.C.

    San Luis Potosí City, 78200, Mexico

  • Centro de Estudios de Investigación Básica y Clínica, S.C.

    Guadalajara, 44690, Mexico

  • Centro de Estudios de Reumatología y Dermatología

    Cali, 760042, Colombia

  • Centro de Investigación Clínica Chapultepec S. A. de C. V.

    Morelia, 58260, Mexico

  • Centro de investigaciones medicas Tucuman

    San Miguel de Tucumán, T4000AXL, Argentina

  • Centrum Medyczne Angelius Provita

    Katowice, 40-611, Poland

  • Centrum Medyczne Plejady

    Krakow, 30-363, Poland

  • Centrum Medyczne Pratia Częstochowa

    Częstochowa, 42-200, Poland

  • ChanRe Rheumatology and Immunology Centre and Research

    Bangalore, 560010, India

  • Cheng Hsin General Hospital

    Taipei, 112, Taiwan

  • Chi Mei Medical Center

    Tainan, 71004, Taiwan

  • China Medical University Hospital

    Taichung, 404, Taiwan

  • Chong-Hua Hospital

    Cebu City, 6000, Philippines

  • Chubu Rosai Hospital

    Nagoya, 455-8530, Japan

  • Chukyo Hospital

    Nagoya, 457-8510, Japan

  • Clinic of Modern Rheumatology

    Kyiv, 02081, Ukraine

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida, 33765, United States

  • Clínica de la costa Ltda.

    Barranquilla, 080020, Colombia

  • Coherence Pain & Arthritis Clinics

    Pune, 411001, India

  • Com Non-Com Entr of Lviv Reg Coun "Lviv Reg Clin Hos, Rheu Dprt, Danylo Halytsky Lviv Nat Med Uni

    Lviv, 79010, Ukraine

  • Communal Enterprise "Hospital #1" of Zhytomyr City Council, Consultation and Treatment Department "Scientific Research Center"

    Zhytomyr, 10002, Ukraine

  • Communal Non-Commercial Enterprise "Cherkasy Regional Hospital of Cherkasy Regional Council"

    Cherkasy, 18009, Ukraine

  • Communal Non-Commercial Enterprise "Khmelnytsky Regional Hospital" of Khmelnytsky Regional Council

    Khmelnytskyi, 29000, Ukraine

  • Communal Non-Commercial Enterprise of Kyiv Regional Council Kyiv Clinical Regional Hospital, Consultation and Diagnostic Center

    Kyiv, 04106, Ukraine

  • Consultorio Médico de Reumatología - Hospital Aranda de la Parra

    León, 37000, Mexico

  • Consultorio Privado de Especialidad

    Guadalajara, 44650, Mexico

  • DCC "Sveta Anna" EOOD

    Sofia, 1750, Bulgaria

  • DCC Equita EOOD

    Varna, 9000, Bulgaria

  • DCC-1-Sevlievo EOOD

    Sevlievo, 5400, Bulgaria

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina, 28210, United States

  • Davao Doctors Hospital

    Davao City, 8000, Philippines

  • Delta Health Care SRL

    Bucharest, 14142, Romania

  • Ebserh Hospital de Clínicas da Universidade Federal de Uberlândia-HC-UFU

    Uberlândia, 38402-028, Brazil

  • Euromedica - Kyanos Stavros

    Thessaloniki, 546 36, Greece

  • Ewha University Mokdong Hospital, Yangcheon-gu

    Seoul, 07985, South Korea

  • Far Eastern Memorial Hospital

    New Taipei City, 220, Taiwan

  • Far Eastern University - Nicanor Reyes Medical Foundation

    Quezon City, 1118, Philippines

  • Fort Sunpasithiprasong Hospital

    Ubon Ratchathani, 34190, Thailand

  • Fundación Respirar

    Buenos Aires, 1426, Argentina

  • Fundación Valle de Lili

    Cali, 760032, Colombia

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, 15090-000, Brazil

  • General Hospital of Athens "Hippokration"

    Athens, 11527, Greece

  • General Hospital of Athens "Laiko"

    Athens, 11527, Greece

  • General Hospital of Thessaloniki "Hippokration"

    Thessaloniki, 546 42, Greece

  • General University Hospital of Larissa

    Larissa, 41110, Greece

  • General University Hospital of Patras

    Pátrai, 26504, Greece

  • Hanyang University Hospital, Seongdong-gu

    Seoul, 04763, South Korea

  • Healthy Medical Center SAS

    Zipaquirá, 250252, Colombia

  • Hiroshima Prefectural Hospital

    Hiroshima, 734-8530, Japan

  • Hiroshima University Hospital

    Hiroshima, 734-8551, Japan

  • Hitachi, Ltd. Hitachinaka General Hospital

    Hitachi-Naka, 312-0057, Japan

  • Hokkaido University Hospital

    Sapporo, 060-8648, Japan

  • Hospital Pablo Tobón Uribe

    Medellín, 050034, Colombia

  • Hospital de Clínicas de Porto Alegre

    Santa Cecília, 90035-903, Brazil

  • Houston MD Medspa and Wellness Clinic

    Houston, Texas, 77084, United States

  • Hyogo Prefectural Amagasaki General Medical Center

    Amagasaki-shi, 660-8550, Japan

  • Hôpital Pitié-Salpêtrière

    Paris, 75013, France

  • ICT (Investigaciones Clínicas Tucumán)

    San Miguel de Tucumán, T4000ICL, Argentina

  • IDEARG (Instituto de Enfermedades Autoinmunes Renato Guzmán)

    Bogotá, 110221, Colombia

  • IMPAR SERVICOS HOSPITALARES S/A ; Hospital São Lucas

    Rio de Janeiro, 22061-080, Brazil

  • INTER CLINIC Piotr Adrian Klimiuk

    Bialystok, 15-077, Poland

  • IR Medical Center /Hospital de Día/ Instituto de Reumatología y Traumatología

    Mendoza, M5500CPH, Argentina

  • IRIS Research and Development, LLC

    Plantation, Florida, 33324-2736, United States

  • IUHW Narita Hospital

    Narita-shi, 286-8520, Japan

  • Instituto CAICI SRL

    Rosario, S2000PBJ, Argentina

  • Instituto Medico CER

    Buenos Aires, B1878DVB, Argentina

  • Instituto Méderi de Pesquisa e Saúde

    Passo Fundo, 99010-120, Brazil

  • Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.

    Zapopan, 45070, Mexico

  • Japanese Red Cross Saitama Hospital

    Saitama-shi, 330-8553, Japan

  • Jose R. Reyes Memorial Medical Center

    Santa Cruz, 1003/1014, Philippines

  • Juntendo University Urayasu Hospital

    Urayasu-shi, 279-0021, Japan

  • Kakogawa Central City Hospital

    Kakogawa-shi, 675-8611, Japan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, 807, Taiwan

  • Keio University Hospital

    Shinjuku, 160-8582, Japan

  • King Chulalongkorn Memorial Hospital

    Bangkok, 10330, Thailand

  • Kobe City Medical Center General Hospital

    Kobe, 650-0047, Japan

  • Kobe University Hospital

    Kobe, 650-0017, Japan

  • KonKuk University Medical Center, Gwangjin-gu

    Seoul, 5030, South Korea

  • Kuwana City Medical Center

    Kuwana-shi, 511-0061, Japan

  • Kyiv City Clinical Hospital #3

    Kyiv, 02125, Ukraine

  • Kyiv Railway Clinical Hospital #2 of Branch "Health Center" of Joint-Stock Company "Ukrainian Railway"

    Kyiv, 03049, Ukraine

  • LMK Servicos Medico S/S

    Porto Alegre, 90480, Brazil

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City, 33305, Taiwan

  • Louisiana State University School of Medicine section of Rheumatology

    New Orleans, Louisiana, 70112, United States

  • Maharaj Nakorn Chiang Mai Hospital, Division of Rheumatology

    Chiang Mai, 50200, Thailand

  • Maharaja Agrasen Superspeciality Hospital

    Jaipur, 302039, India

  • Makati Medical Center

    Makati, 1229, Philippines

  • Malwa-Med Iwona Chlebicka

    Wroclaw, 50-304, Poland

  • Mary Mediatrix Medical Center

    Lipa, 4217, Philippines

  • Małopolskie Badania Kliniczne

    Krakow, 30-002, Poland

  • Medical Center of Limited Liability Company "Kalyna. Center of Modern Medicine

    Lviv, 79034, Ukraine

  • Medical Centre "Academical Medical Group" LLC

    Lviv, 79044, Ukraine

  • Municipal Nonprofit Institution "Vinnytsia City Clinical Hospital #1"

    Vinnytsia, 21029, Ukraine

  • Nagasaki University Hospital

    Nagasaki, 852-8501, Japan

  • Nagoya City University Hospital

    Nagoya, 467-8602, Japan

  • National Hospital Organization Chiba Medical Center Chibahigashi National Hospital

    Chiba, 260-8712, Japan

  • National Hospital Organization Hokkaido Medical Center

    Sapporo, 063-0005, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, 810-8563, Japan

  • National Hospital Organization Tokyo Medical Center

    Meguro-ku, 152-8902, Japan

  • National Kohnodai Medical Center, Japan Institute for Health Security

    Ichikawa-shi, 272-8516, Japan

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • Naval Hospital of Athens

    Athens, 115 21, Greece

  • Neomed Brasov

    Brasov, 500285, Romania

  • Niigata University Medical and Dental Hospital

    Niigata, 951-8520, Japan

  • Nizam's Institute of medical Sciences

    Hyderabad, 500082, India

  • Okayama City General Medical Center Okayama City Hospital

    Okayama, 700-8557, Japan

  • Ome Medical Center

    Ome-shi, 198-0042, Japan

  • Omega Research MetroWest, LLC

    DeBary, Florida, 32713, United States

  • Osaka Saiseikai Nakatsu Hospital

    Osaka, 530-0012, Japan

  • Outpatient Clinic for Specialized Outpatient Medical Care - Medical Center Kyuchuk Parizh Ltd.

    Plovdiv, 4004, Bulgaria

  • Phramongkutklao Hospital (PMK)

    Bangkok, 10400, Thailand

  • Preventive Care SAS

    Chía, 250001, Colombia

  • Private Small-Scale Enterprise Medical Centre "Pulse", Therapeutical Department

    Vinnytsia, 21001, Ukraine

  • Professional research Center INC

    Miami, Florida, 33172, United States

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Radiance Hospital

    Nagpur, 380009, India

  • Rajavithi Hospital

    Bangkok, 10400, Thailand

  • Rajiv Gandhi Government General Hospital

    Chennai, 600003, India

  • Ramathibodi Hospital

    Bangkok, 10400, Thailand

  • Rheumatology Care Center, PLLC

    Bellaire, Texas, 77041, United States

  • SC Medaudio-Optica SRL

    Râmnicu Vâlcea, 240762, Romania

  • SER - Serviços Especializados em Reumatologia da Bahia

    Salvador, 40150-150, Brazil

  • SERVIMED S.A.S Bucaramanga

    Bucaramanga, 680003, Colombia

  • SMIQ, S. de R.L. de C.V.

    Querétaro, 76070, Mexico

  • Saga University Hospital

    Saga, 849-8501, Japan

  • Sainokuni Higashiomiya Medical Center

    Saitama-shi, 331-8577, Japan

  • Sangini Hospital

    Ahmedabad, 380015, India

  • Santa Casa de Belo Horizonte

    Belo Horizonte, 30150-320, Brazil

  • Seoul National University Hospital

    Junggu, 03080, South Korea

  • Seoul Saint Mary's Hospital of the Catholic University of Korea, Seocho-gu

    Seoul, 6591, South Korea

  • Shin-Kokura Hospital

    Kitakyushu-shi, 803-8505, Japan

  • Showa Medical University East Hospital

    Shinagawa-ku, 142-0054, Japan

  • Shree Hospital and Critical Care Centre.

    Nagpur, 440009, India

  • Songklanagarind Hospital

    Songkhla, 90110, Thailand

  • SouthCoast Research Center, Inc.

    Miami, Florida, 33136, United States

  • Spitalul Clinic Judetean de Urgentã Craiova

    Craiova, 200642, Romania

  • Srinagarind Hospital, Khon Kaen University

    Khon Kaen, 40002, Thailand

  • St.Luke's International Hospital

    Chūōku, 104-8560, Japan

  • State Ins Nat Scie Cen M.D.Strazhesko Ins of Cardio Clin

    Kyiv, 03151, Ukraine

  • Sun Research Institute

    San Antonio, Texas, 78215, United States

  • TRI-Service General Hospital

    Taipei, 114, Taiwan

  • Taipei Medical University Hospital

    Taipei, 110, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • The University of Tokyo Hospital

    Bunkyō City, 113-8655, Japan

  • Toho University - Ohashi Medical Center

    Meguro-ku, 153-8515, Japan

  • Toho University Omori Medical Center

    Ōta-ku, 143-8541, Japan

  • Toho University Sakura Medical Center

    Sakura-shi, 285-8741, Japan

  • Tohoku Medical and Pharmaceutical University Hospital

    Sendai, 983-8512, Japan

  • Tokai University Hospital

    Isehara-shi, 259-1193, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, 162-8666, Japan

  • Tomakomai City Hospital

    Tomakomai-shi, 053-8567, Japan

  • Toyama University Hospital

    Toyama, 930-0194, Japan

  • UP-PGH

    Manila, 1000, Philippines

  • Unidad de Atención Médica e Investigación en Salud

    Mérida, 97000, Mexico

  • Unidad de Investigaciones Reumatológicas A.C

    San Luis Potosí City, 78290, Mexico

  • Unity Hospital and Trauma Centre

    Surat, 395010, India

  • University General Hospital "Attikon"

    Athens, 124 62, Greece

  • University Multi-profile Hospital for Active Treatment - Plovdiv AD

    Plovdiv, 4001, Bulgaria

  • University of Colorado Denver

    Aurora, Colorado, 80045, United States

  • University of Fukui Hospital

    Yoshida-gun, 910-1193, Japan

  • University of Miyazaki Hospital

    Miyazaki, 889-1692, Japan

  • University of Oklahoma College of Medicine

    Oklahoma City, Oklahoma, 73117, United States

  • University of Yamanashi Hospital

    Chuo-shi, 409-3898, Japan

  • Uzhhorod City Multidisciplinary Clinical Hospital

    Uzhhorod, 88000, Ukraine

  • Vajira Hospital

    Bangkok, 10300, Thailand

  • Velocity Nova Sp. z o. o.

    Lublin, 20-362, Poland

  • Vijaya Ortho & Trauma Centre

    Sadashivnagar, 590001, India

  • Vita Longa Sp. z o.o.

    Katowice, 40-748, Poland

  • Volyn Regional Clinical Hospital

    Lutsk, 43000, Ukraine

  • Yokohama City Minato Red Cross Hospital

    Yokohama, 231-8682, Japan

  • Zespół Poradni Specjalistycznych REUMED

    Lublin, 20-607, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.